Moderna intends to file for the emergency use authorization (EUA) of COVID vaccine for kids aged around six months to five years to the US health regulators. This application will be submitted by the end of April. The vaccine was being tested during the emergence of the Omicron variant. Two doses of the vaccine proved to be 44% effective in children belonging to the age group of six months to two years, informs the drugmaker.
Read More from Reuters